Pulmonary pharmacology & therapeutics最新文献

筛选
英文 中文
Experimental modeling of pulmonary fibrosis and combined emphysema in mice using repeated doses of bleomycin and cigarette smoke extract 使用重复剂量的博来霉素和香烟烟雾提取物对小鼠肺纤维化和合并肺气肿的实验建模
IF 3.3 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2025-06-28 DOI: 10.1016/j.pupt.2025.102376
Jung Hur , Chin Kook Rhee , Joon Young Choi , Yong Suk Jo
{"title":"Experimental modeling of pulmonary fibrosis and combined emphysema in mice using repeated doses of bleomycin and cigarette smoke extract","authors":"Jung Hur ,&nbsp;Chin Kook Rhee ,&nbsp;Joon Young Choi ,&nbsp;Yong Suk Jo","doi":"10.1016/j.pupt.2025.102376","DOIUrl":"10.1016/j.pupt.2025.102376","url":null,"abstract":"<div><h3>Rationale</h3><div>A high prevalence of smoking among idiopathic pulmonary fibrosis (IPF) patients increases the risk of emphysema. Combined pulmonary fibrosis and emphysema (CPFE) occurs predominantly in males, characterized by severe exercise-induced dyspnea, decreased diffusing capacity, and increased lung cancer risk. The exclusion of CPFE patients from clinical studies has limited understanding of its pathophysiology, treatment, and prognosis. This study aimed to close this knowledge gap by comparing CPFE with pure IPF in animal models, with the intent of developing phenotype-directed therapeutic strategies.</div></div><div><h3>Methods</h3><div>Eight-week-old female C57BL/6J mice received biweekly intratracheal bleomycin (BLM, 2 U/kg/100 μL) for 3 doses. For the CPFE model, additional intranasal cigarette smoke extract (CSE) was administered twice weekly. Inflammation and fibrosis were evaluated through bronchoalveolar lavage fluid (BALF), proinflammatory cytokines, fibrosis markers, and lung histology.</div></div><div><h3>Results</h3><div>BALF analysis showed increased cell counts in all BLM-treated groups, primarily macrophages, with elevated interleukin (IL)-6, transforming growth factor (TGF)-β1, and matrix metalloproteinases (MMP 3 and MMP 8). The BLM and CSE treated group displayed higher macrophages and lymphocytes counts than BLM alone. Lung tissue analysis revealed increased hydroxyproline, inflammation scores, Ashcroft scores, and higher α-smooth muscle actin (SMA) and collagen 1 expression in BLM-treated groups. The BLM and CSE treated group demonstrated notably higher emphysema formation as measured by mean linear intercept (MLI).</div></div><div><h3>Conclusions</h3><div>Through repeated BLM administrations and CSE exposure, an effective model for persistent pulmonary fibrosis and emphysema was established, enabling preclinical studies on CPFE and IPF and exploration of phenotype-directed therapeutic strategies for pulmonary fibrosis.</div></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"90 ","pages":"Article 102376"},"PeriodicalIF":3.3,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144523904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The era of multiple biologics: Is combination and switching an option in the management of severe asthma? 多种生物制剂的时代:联合和转换是治疗严重哮喘的一种选择吗?
IF 3.3 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2025-06-19 DOI: 10.1016/j.pupt.2025.102375
Emmanuel Oshiogwe Okwuofu , Audrey Chee Hui Yong , Jonathan Chee Woei Lim , Johnson Stanslas
{"title":"The era of multiple biologics: Is combination and switching an option in the management of severe asthma?","authors":"Emmanuel Oshiogwe Okwuofu ,&nbsp;Audrey Chee Hui Yong ,&nbsp;Jonathan Chee Woei Lim ,&nbsp;Johnson Stanslas","doi":"10.1016/j.pupt.2025.102375","DOIUrl":"10.1016/j.pupt.2025.102375","url":null,"abstract":"<div><h3>Background and objective</h3><div>The introduction of biologics therapies targeting specific cytokines relevant to asthma pathophysiology has changed the landscape in the treatment of severe asthma in both adults and children. However, the availability of multiple agents, inclusion criteria for randomised control trials (RCTs), variation in national and international guidelines, instances of treatment failures, and the potential of switching or combining biologic therapies, highlight the need for real-world evidence. Data from real-world studies of biologics in severe asthma may complement efficacy data obtained from RCTs and provide important post-marketing safety information. Additionally, these studies may help inform the design of future clinical trials, characterise the natural history of the disease, and support important translational research. This review highlights current evidence for the combination and switching of biologics in severe asthma and comorbid diseases that may serve as pointers for optimal clinical outcomes.</div></div><div><h3>Method</h3><div>Pubmed, Scopus, and Web of Science were searched using specified search strategies.</div></div><div><h3>Results</h3><div>Available evidence suggests that patients with severe asthma who received combination or switched biologics (omalizumab, benralizumab, reslizumab, mepolizumab, dupilumab, and Tezepelumab) in real-world settings experienced significant improvement in asthma control, exacerbation, and lung function. Although combining biologics is not currently a common practice, there are cases where biologic therapies were combined, discontinued, or switched.</div></div><div><h3>Conclusion</h3><div>Patients may benefit from the early and systematic consideration of combination and switching of biologic therapies in severe asthma.</div></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"90 ","pages":"Article 102375"},"PeriodicalIF":3.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhaled epoprostenol for management of acute respiratory failure and pulmonary vascular disease 吸入环氧前列醇治疗急性呼吸衰竭和肺血管疾病
IF 3.3 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2025-06-11 DOI: 10.1016/j.pupt.2025.102374
Daniel Connelly , Jessica Delahanty , Shyam Patel , Kimberly A. Ackerbauer , Nicholas A. Bosch , Elizabeth S. Klings , Justin K. Lui
{"title":"Inhaled epoprostenol for management of acute respiratory failure and pulmonary vascular disease","authors":"Daniel Connelly ,&nbsp;Jessica Delahanty ,&nbsp;Shyam Patel ,&nbsp;Kimberly A. Ackerbauer ,&nbsp;Nicholas A. Bosch ,&nbsp;Elizabeth S. Klings ,&nbsp;Justin K. Lui","doi":"10.1016/j.pupt.2025.102374","DOIUrl":"10.1016/j.pupt.2025.102374","url":null,"abstract":"<div><div>Inhaled epoprostenol has remained an attractive and viable option for the delivery of prostacyclin to offset abnormalities in ventilation and perfusion mismatch while minimizing the typical adverse effects associated with systemic administration. There is a need to better understand pharmacologic properties of inhaled epoprostenol and its application to diseases affecting the cardiopulmonary system. The goal of this review is to provide an overview of inhaled epoprostenol and outline its use specifically in the medical management of acute hypoxemic respiratory failure and pulmonary vascular disease. Among patients with acute respiratory distress syndrome who ultimately required invasive ventilation, inhaled epoprostenol has not improved ventilator-free days, intensive care unit length of stay, or mortality. However, it may be beneficial in certain select patient populations. In the management of pulmonary hypertension, inhaled epoprostenol has allowed for continued maintenance of chronic pulmonary arterial hypertension-specific therapy and for possibly improving right ventricular function as an attractive option in the critical care management of pulmonary hypertension.</div></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"90 ","pages":"Article 102374"},"PeriodicalIF":3.3,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144272530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation 新型大环内酯EP395对急性中性粒细胞性气道炎症的影响
IF 3.3 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2025-06-03 DOI: 10.1016/j.pupt.2025.102364
Jennifer Ann Kricker , Virginia Norris , Clive Page , Michael John Parnham
{"title":"Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation","authors":"Jennifer Ann Kricker ,&nbsp;Virginia Norris ,&nbsp;Clive Page ,&nbsp;Michael John Parnham","doi":"10.1016/j.pupt.2025.102364","DOIUrl":"10.1016/j.pupt.2025.102364","url":null,"abstract":"<div><div>Macrolide antibiotics have been shown to reduce exacerbations of respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. This effect is believed to be due to the immunomodulatory properties of macrolides rather than their antimicrobial activity. However, prolonged use of macrolide antibiotics can result in the development of antimicrobial resistance, which prompted us to develop EP395, a compound with similar pharmacological actions to macrolides, but without antimicrobial activity. We investigated EP395 in several established models of neutrophilic airway inflammation in male BALB/c mice. Oral pretreatment with EP395 for 2 weeks had significant anti-inflammatory effects, reducing cytokines and neutrophil infiltration into bronchoalveolar lavage fluid (BAL) induced by either lipopolysaccharide (LPS), tobacco smoke or respiratory syncytial virus (RSV). EP395 had comparable inhibitory effects to azithromycin in all three models. The PDE4 inhibitor, roflumilast, was also included as a positive control in the LPS model, with comparable effects on neutrophil numbers. In vitro assays on neutrophil function revealed both stimulatory and inhibitory effects of treatment with EP395. These data demonstrate the beneficial pharmacological activity of EP395, a macrolide with negligible antimicrobial activity, in models of acute neutrophilic inflammation and on neutrophil activity and supported its progression into clinical development as a potential treatment for COPD.</div></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"90 ","pages":"Article 102364"},"PeriodicalIF":3.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of Dry Powder Inhaler formulation for site specific delivery of nanoconjugates loaded with Curcumin and BCL2 siRNA in Lung Cancer 用于肺癌中姜黄素和BCL2 siRNA负载纳米偶联物位点特异性递送的干粉吸入剂配方的开发
IF 3.3 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2025-06-03 DOI: 10.1016/j.pupt.2025.102361
Madhuchandra Lahan , Trideep Saikia , Rinku Baishya , Alakesh Bharali , Sunayana Baruah , Shatabdi Ghose , Nikhil Biswas , Damiki Laloo , Subhash Medhi , Bhanu P Sahu
{"title":"Development of Dry Powder Inhaler formulation for site specific delivery of nanoconjugates loaded with Curcumin and BCL2 siRNA in Lung Cancer","authors":"Madhuchandra Lahan ,&nbsp;Trideep Saikia ,&nbsp;Rinku Baishya ,&nbsp;Alakesh Bharali ,&nbsp;Sunayana Baruah ,&nbsp;Shatabdi Ghose ,&nbsp;Nikhil Biswas ,&nbsp;Damiki Laloo ,&nbsp;Subhash Medhi ,&nbsp;Bhanu P Sahu","doi":"10.1016/j.pupt.2025.102361","DOIUrl":"10.1016/j.pupt.2025.102361","url":null,"abstract":"<div><div>Lung cancer remains one of the leading causes of cancer-related deaths, with current chemotherapy limited by poor drug delivery, toxicity, and resistance. To overcome these challenges, we developed a dry powder inhaler (DPI) system incorporating a PLGA-PEG-LHRH (PPL) nanoconjugate (NC) for enhanced delivery. Curcumin (CUR), with known anticancer and P-gp inhibition properties, was co-loaded with bcl2 siRNA (bclsR) to target bcl2 protein and combat resistance mechanisms.</div><div>The CUR and bclsR-loaded PLGA NC (172.12 ± 24.23 nm) were prepared using double emulsion solvent evaporation (DESE) method and converted into DPI using a carbohydrate carrier, showing a mass mean aerodynamic diameter of 4.62 μm and fine particle fraction of 65.39 ± 0.19 %, ideal for lung delivery. Animal studies showed that DPI delivered via tracheal administration in lung cancer models exhibited superior anticancer effects compared to free CUR, particularly in terms of pathological improvements and upregulation of cancer markers like P53 and TNF-α.</div><div><em>In vivo</em> biodistribution studies in tumor-bearing mice revealed higher CUR concentrations in plasma (326.85 ± 6.17 μg) and lungs (207.03 ± 4.11 μg), with enhanced systemic exposure as indicated by higher AUC and Cmax values. These findings suggest that CUR-siRNA loaded DPI could provide an effective therapeutic approach for lung cancer.</div></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"90 ","pages":"Article 102361"},"PeriodicalIF":3.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial 新型抗炎大环内酯EP395在健康志愿者吸入脂多糖刺激模型中的作用:一项随机对照试验
IF 3.3 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2025-06-03 DOI: 10.1016/j.pupt.2025.102365
Jens M. Hohlfeld , Philipp Badorrek , Olof Breuer , Kate Hanrott , Jennifer Kricker , Michael J. Parnham , Virginia Norris
{"title":"Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial","authors":"Jens M. Hohlfeld ,&nbsp;Philipp Badorrek ,&nbsp;Olof Breuer ,&nbsp;Kate Hanrott ,&nbsp;Jennifer Kricker ,&nbsp;Michael J. Parnham ,&nbsp;Virginia Norris","doi":"10.1016/j.pupt.2025.102365","DOIUrl":"10.1016/j.pupt.2025.102365","url":null,"abstract":"<div><div>EP395, a macrolide with negligible antimicrobial activity but with anti-inflammatory effects in murine lipopolysaccharide (LPS) challenge model, is being developed as a potential treatment to reduce COPD exacerbations. This double-blind, placebo-controlled clinical study evaluated the pharmacodynamics of EP395 in response to inhaled LPS, an established clinical model for assessing anti-inflammatory effects of potential new treatments.</div><div>Forty-nine healthy, non-smoking participants were randomised to oral 375 mg EP395 or placebo, daily for 3 weeks. An inhaled LPS challenge (2 μg) was then given, followed 6 h later by bronchoscopy for bronchoalveolar lavage fluid (BALF) collection. Blood samples were collected pre, 6 and 24 h after LPS challenge.</div><div>BALF concentrations of IL-6, TNF-α, MIP-1α, MIP-1β and MCP-1 were lower with EP395 than placebo, while IL-33, IL-8, and IL-1β were higher with EP395 than placebo (not statistically significant). Neutrophil counts were unaffected, but neutrophil elastase and myeloperoxidase were higher with EP395 than placebo (not statistically significant). Serum concentrations of surfactant protein-D significantly increased in the EP395 group in response to LPS at both 6 and 24 h compared with pre-LPS (mean pre-LPS 148.8 ng/mL; mean 24 h post-LPS 183.0 ng/mL) but not in the placebo group (mean pre-LPS 142.4 ng/mL; mean 24 h post-LPS 142.4 ng/mL). The log<sub>2</sub> transformed fold difference in the EP395 group, before and 24 h after LPS challenge was 0.33 (95 % CI 0.52, 0.14; p = 0.0007).</div><div>EP395 treatment increased the host defence response to inhaled LPS, including the epithelial response, whilst reducing inflammatory site pro-inflammatory mediators.</div></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"90 ","pages":"Article 102365"},"PeriodicalIF":3.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier 一种新型大环内酯EP395,具有降低抗菌活性和增强呼吸道上皮屏障的作用
IF 3.3 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2025-06-03 DOI: 10.1016/j.pupt.2025.102363
Thorarinn Gudjonsson , Jon Petur Joelsson , Ari Jon Arason , Arni Asbjarnarson , Fridrik Runar Gardarsson , Fredrik Lehmann , Peter Teodorovic , Saevar Ingthorsson , Snaevar Sigurdsson , Bryndis Valdimarsdottir , Michael John Parnham , Clive Page , Jennifer Ann Kricker
{"title":"A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier","authors":"Thorarinn Gudjonsson ,&nbsp;Jon Petur Joelsson ,&nbsp;Ari Jon Arason ,&nbsp;Arni Asbjarnarson ,&nbsp;Fridrik Runar Gardarsson ,&nbsp;Fredrik Lehmann ,&nbsp;Peter Teodorovic ,&nbsp;Saevar Ingthorsson ,&nbsp;Snaevar Sigurdsson ,&nbsp;Bryndis Valdimarsdottir ,&nbsp;Michael John Parnham ,&nbsp;Clive Page ,&nbsp;Jennifer Ann Kricker","doi":"10.1016/j.pupt.2025.102363","DOIUrl":"10.1016/j.pupt.2025.102363","url":null,"abstract":"<div><div>Epithelial barrier failure, a feature of several inflammatory lung diseases, contributes to exacerbations and disease progression. Acute exacerbations are often treated with macrolides, including azithromycin (AZM). In part, this is due to both primary antimicrobial and additional immunomodulatory actions, complemented by recently reported enhanced integrity of respiratory epithelial barriers. However, long-term “off label” use of macrolides is associated with increased bacterial resistance. We now introduce a new class of compounds, “Barriolides” that are analogues of AZM promoting airway epithelial barrier integrity <em>in vitro</em>, with negligible antibacterial activity. The lead compound is EP395 which does not affect cell viability up to 100 μM in VA10 bronchial epithelial cells. Treatment with EP395 for three weeks enhanced epithelial barrier integrity, measured by increased transepithelial electrical resistance, reduced paracellular flux in air-liquid interface culture and increased expression of tight junction proteins. EP395 also induced epidermal differentiation and formation of lamellar bodies, complemented by a relevant genetic footprint. In mice exposed to sulphur dioxide, pre-treatment with EP395 reduced extravasation of human serum albumin into the bronchoalveolar lavage fluid. These data demonstrate epithelial barrier-protecting effects of EP395, a promising candidate for treatment of chronic respiratory diseases without risk of bacterial resistance.</div></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"90 ","pages":"Article 102363"},"PeriodicalIF":3.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144230280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitigating systemic corticosteroid risks in COPD: A call for earlier triple therapy initiation 减轻慢性阻塞性肺病的全身皮质类固醇风险:呼吁尽早开始三联治疗
IF 3.3 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2025-06-03 DOI: 10.1016/j.pupt.2025.102360
Luis J. Nannini
{"title":"Mitigating systemic corticosteroid risks in COPD: A call for earlier triple therapy initiation","authors":"Luis J. Nannini","doi":"10.1016/j.pupt.2025.102360","DOIUrl":"10.1016/j.pupt.2025.102360","url":null,"abstract":"<div><div>Current GOLD guidelines recommend initial dual therapy with a LABA and LAMA for COPD patients with a high risk of exacerbations (at least two moderate or one severe exacerbation in the previous 12 months), with Inhaled Corticosteroids (ICS) added for specific phenotypes or continued exacerbations. Systemic corticosteroids (SCS) are advised for severe exacerbations, but cumulative SCS exposure is linked to significant adverse outcomes such as endocrine disorders and pneumonia. Studies suggest that after limited exacerbations, COPD patients may exhaust their “SCS credit,” increasing their risk of severe comorbidities. Earlier initiation of triple therapy in high-risk, symptomatic patients shows substantial benefits, including improved quality of life, compared to standard care. Like asthma management, SCS exposure in COPD should be minimised, and precision medicine should guide early triple therapy to preserve SCS use for future exacerbations.</div></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"90 ","pages":"Article 102360"},"PeriodicalIF":3.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144230281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted inhibition of IDO1 by Kushenol A enhances radiosensitivity in non-small cell lung cancer 苦参酚A靶向抑制IDO1增强非小细胞肺癌的放射敏感性。
IF 3.3 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2025-06-03 DOI: 10.1016/j.pupt.2025.102362
Yingwei Zhu , Yunqian Chu , Hanjue Dai , Enci Lu , Qian Geng , Qingying Xian , Hua Jiang , Wenyu Zhu
{"title":"Targeted inhibition of IDO1 by Kushenol A enhances radiosensitivity in non-small cell lung cancer","authors":"Yingwei Zhu ,&nbsp;Yunqian Chu ,&nbsp;Hanjue Dai ,&nbsp;Enci Lu ,&nbsp;Qian Geng ,&nbsp;Qingying Xian ,&nbsp;Hua Jiang ,&nbsp;Wenyu Zhu","doi":"10.1016/j.pupt.2025.102362","DOIUrl":"10.1016/j.pupt.2025.102362","url":null,"abstract":"<div><div>Kushenol, a monomeric compound, was extracted from the roots of the medicinal plant Sophora flavescens. To explore the activity of Kushenol A in non-small cell lung cancer (NSCLC), CCK-8 assay, flow cytometry, and Western blot were performed. A xenograft mouse model was established. Our results demonstrated that Kushenol A treatment significantly enhanced the killing effect of radiation on NSCLC cells. Co-treatment with radiation and Kushenol A markedly reduced cell viability, increased intracellular ROS levels, and elevated the proportion of apoptotic cells compared to NSCLC cells treated with radiation alone. Animal experiments further confirmed that radiation therapy with simultaneous Kushenol A administration suppressed tumor growth and improved radiotherapy sensitivity compared to mice treated with radiation alone. Furthermore, Kushenol A did not produce significant toxic damage to the major organs of mice. Mechanistically, radiation therapy combined with Kushenol A treatment significantly upregulated protein levels of cleaved Caspase-3 and cleaved Caspase-9, leading to Bax translocation from the cytoplasm to mitochondria. Concurrently, Kushenol A treatment reduced NRF2 levels in the cytoplasm, thereby promoting an increase in ROS levels. Notably, Kushenol A enhanced tumor radiosensitivity by targeted inhibition of Indoleamine 2,3-dioxygenase 1 (IDO1). Taken together, our findings suggested that cotreatment with Kushenol A and radiation promoted the entry of Bax into mitochondria and activated the mitochondrial apoptotic pathway. Kushenol A exhibited targeted inhibition of IDO1, enhancing the sensitivity of non-small cell lung cancer to radiotherapy.</div></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"90 ","pages":"Article 102362"},"PeriodicalIF":3.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The low global warming potential propellant HFA-152a does not induce bronchoconstriction or impair mucociliary clearance 低全球变暖潜势推进剂HFA-152a不会引起支气管收缩或损害纤毛粘膜清除。
IF 3.3 3区 医学
Pulmonary pharmacology & therapeutics Pub Date : 2025-04-05 DOI: 10.1016/j.pupt.2025.102358
Michela Salvadori , Dave Singh , Kusum Mathews , Luca Girardello , Mauro Cortellini , Aida Emirova , Ilaria Pacchetti , Martina Foti , Veronica Puviani , Gianluigi Poli , François Rony
{"title":"The low global warming potential propellant HFA-152a does not induce bronchoconstriction or impair mucociliary clearance","authors":"Michela Salvadori ,&nbsp;Dave Singh ,&nbsp;Kusum Mathews ,&nbsp;Luca Girardello ,&nbsp;Mauro Cortellini ,&nbsp;Aida Emirova ,&nbsp;Ilaria Pacchetti ,&nbsp;Martina Foti ,&nbsp;Veronica Puviani ,&nbsp;Gianluigi Poli ,&nbsp;François Rony","doi":"10.1016/j.pupt.2025.102358","DOIUrl":"10.1016/j.pupt.2025.102358","url":null,"abstract":"<div><h3>Introduction</h3><div>Use of propellants with high global warming potential (e.g., HFA-134a) for pressurised metered-dose inhalers is being phased down. An alternative is reformulation using propellants with low global warming potential (e.g., HFA-152a), which requires evaluation of the propellant's safety, in particular whether it induces bronchoconstriction or impairs mucociliary clearance (MCC). In this manuscript, we describe two studies, the first comparing the bronchoconstriction potential of HFA-152a vs HFA-134a, the second comparing their effect on MCC.</div></div><div><h3>Methods</h3><div>The bronchoconstriction study was single-dose, randomised, double-blind, controlled, crossover, in adults with asthma. The primary endpoint was relative change from baseline in forced expiratory volume in 1 s (FEV<sub>1</sub>) at 15 min post-dose.</div><div>The MCC study was multiple-dose (8 days), randomised, open-label, controlled, crossover, in healthy volunteers. The primary endpoint was percent particle retention in the right whole lung at 2 and 4 h after inhalation of radiolabelled particles (PPR<sub>2</sub> and PPR<sub>4</sub>).</div></div><div><h3>Results</h3><div>For the bronchoconstriction study (N = 25), the 95 % CI of the adjusted mean FEV<sub>1</sub> difference between HFA-152a vs HFA-134a at 15 min post-dose was within the −10 % to +10 % equivalence limit (1.86 % [95 % CI –0.48 %, 4.20 %]; p = 0.113). Treatment-emergent adverse events were reported by 4.0 % (HFA-152a) and 12.0 % (HFA-134a) patients, all mild or moderate in intensity, and none serious.</div><div>For the MCC study (N = 20), the 95 % CIs for the adjusted mean differences between HFA-152a vs HFA-134a at Day 8 contained 0 for both PPR<sub>2</sub> (1.36 [–2.28, 4.99]%; p = 0.442) and PPR<sub>4</sub> (0.70 [–1.73, 3.12]%; p = 0.553). A similar proportion of subjects had treatment-emergent adverse events (25.0 % vs 35.0 %), all mild in intensity, and none serious.</div></div><div><h3>Conclusions</h3><div>These two studies suggest a switch in propellant from HFA-134a to HFA-152a is unlikely to induce post-dose bronchoconstriction in asthma or impact lung MCC, and is not accompanied by any safety concerns.</div></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"89 ","pages":"Article 102358"},"PeriodicalIF":3.3,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信